The LSIMF will provide £60 million in capital grants for investment in the manufacture of:

• human medicines (drug substance and drug product)
• medical diagnostics
• MedTech products

We particularly encourage applications from companies ready to deploy their emerging technologies at scale in commercial manufacturing.

Phases

The fund will be in 2 phases (March to May 2022 and September to November 2022), with monthly deadlines to submit EOIs.

Phase 2 closing dates:

• Wave 4: Friday 30 September 2022, 12pm (noon)
• Wave 5: Monday 31 October 2022, 12pm (noon)
• Wave 6: Wednesday 30 November 2022, 12pm (noon)

Eligibility

This is a summary of the minimum requirements for ‘in scope’ projects (read the scheme guidance for full details):

Your manufacturing investment must relate to the manufacture of:

Human medicines (this includes both the manufacture of active pharmaceutical ingredients (API) / drug substance and finished product / drug product). The fund is open to applications across the breadth of types of MHRA licenced medicines for human use, OR Diagnostics – for both disease identification and monitoring in human health, OR Medical devices – all types of medical devices related to human health

Your project must:

Be a manufacturing project: this could be manufacturing product for clinical trials or for commercial sale, AND Be located in the UK, AND Have a total investment value of more than £12 million.

Your project can:

Be for the upgrade or expansion of an existing facility or the establishment of a new manufacturing facility.

We will not accept applications that propose to manufacture:

• veterinary medicines
• herbal supplements and vitamins
• input materials
• consumables or equipment suppliers (for example vials, syringes)

Fund objectives

We will prioritise applicants based on their alignment to the fund’s objectives:

1. Creating economic opportunity through investments that will provide high-wage, high-skilled jobs.
2. Deploying cutting-edge innovations (at both pilot and commercial scale) which can be embedded in either the product itself or the manufacturing process.
3. Increasing health resilience, either through increased domestic capacity or by providing flexible capabilities that can be re-deployed in some way in a future health emergency.
4. Minimising impact on the environment, which might include reduction in input resources or using alternative input materials to become more sustainable or support the government’s net zero target.

How to apply

The assessment has 2 stages:

• Stage 1: Expression of Interest (EOI)
• Stage 2: Fund Application

We will use a rapid decision-making process to identify projects that align with the Fund’s objectives 2 to 4 using an EOI stage.

Projects that meet the requirements of the EOI will be invited to submit a Fund Application to determine the economic impact of the investment (objective 1) and test the project against standard requirements for grant funding.